FAP-specific signalling is an independent diagnostic approach in ACC and not a surrogate marker of MRI sequences

• Verfasst von: Liew, Dawn [VerfasserIn]
• Verfasst von: Röhrich, Manuel [VerfasserIn]
• Verfasst von: Loi, Lisa [VerfasserIn]
• Verfasst von: Adeberg, Sebastian [VerfasserIn]
• Verfasst von: Syed, Mustafa [VerfasserIn]
• Verfasst von: Gutjahr, Ewgenija [VerfasserIn]
• Verfasst von: Schlemmer, Heinz-Peter [VerfasserIn]
• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Verfasst von: Bendszus, Martin [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Paech, Daniel [VerfasserIn]
• Titel: FAP-specific signalling is an independent diagnostic approach in ACC and not a surrogate marker of MRI sequences
• Verf.angabe: Dawn P. Liew, Manuel Röhrich, Lisa Loi, Sebastian Adeberg, Mustafa Syed, Ewgenija Gutjahr, Heinz Peter Schlemmer, Frederik L. Giesel, Martin Bendszus, Uwe Haberkorn and Daniel Paech
• E-Jahr: 2022
• Jahr: 31 August 2022
• Umfang: 12 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 27.10.2022
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2022
• Band/Heft Quelle: 14(2022), 17 vom: Aug., Artikel-ID 4253, Seite 1-12
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers14174253
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: ACC
• Sach-SW: adenoid cystic carcinoma
• Sach-SW: FAP
• Sach-SW: fibroblast activation protein
• Sach-SW: MRI
• Sach-SW: pixelwise correlation
• Sach-SW: positron emission tomography
• K10plus-PPN: 1820210332

Abstract

Background: Fibroblast Activation Protein (FAP) is a new target for positron emission tomography and computed tomography (PET/CT) imaging of epithelial tumours embedded in a fibrous stroma. Adenoid cystic carcinomas (ACCs) have shown elevated tracer uptake in 68Gallium (68Ga)-labelled FAPIs in previous studies. The current gold standard for ACC imaging is contrast-enhanced (ce) MRI, where intertumoural heterogeneity leads to variable appearance on T1-weighted (T1w) and T2-weighted (T2w) images. In this retrospective analysis, we correlated 68Ga-FAPI PET signalling at three time points with ceT1w and T2w MRI signals to further characterise the significance of 68Ga-FAPI uptake in ACCs. Methods: Clinical PET/CT scans of 12 ACC patients were performed at 10, 60 and 180 min post i.v. administration of 68Ga-labelled-FAPI tracer molecules. 68Ga-PET- and corresponding MRI-scans were co-registered, and 3D volumetric segmentations were performed on ceT1w and T2w lesions of co-registered MRI slides. Signal intensity values of 68Ga-FAPI PET signalling and ceT1w/T2w MRI scans were analysed for their pixelwise correlation in each patient. Pooled estimates of the correlation coefficients were calculated using the Fisher z-transformation. Results: 68Ga-FAPI PET signals showed a very weak positive correlation with ceT1w values (pooled correlation 0.114, 0.147 and 0.162 at 10, 60 and 180 min) and a weak negative correlation with T2w values (pooled correlation −0.148, −0.121 and −0.225 at 10, 60 and 180 min). Individual r-values at 60 min ranged from −0.130 to 0.434 in ceT1w and from −0.466 to 0.637 in T2w MRI scans. Conclusion: There are only slight correlations between the intensity of 68Ga-FAPI PET signals and tumour appearance in ceT1w or T2w MRI scans, which underlines that 68Ga-FAPI PET signalling is not a surrogate marker of MRI sequences but an independent signal.